GNPX Reports Positive Clinical Data for Reqorsa Gene Therapy, Biomarkers Trop-2 and PTEN Correlate with Prolonged PFS in NSCLC Patients
Genprex, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $0.78
-8.2% in 1d after detection
Post-detection moves
1h
-1.5%
1d
-8.2%
3d
-7.9%
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS